Transarterial chemoembolization of liver metastases in patients with uveal melanoma

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

“…Applied cytostatic agents included cisplatin, fotemustine mitomycin C, and BCNU [550,553,554,558,561,562,565,566]. In the largest trial with 42 cutaneous melanoma patients with suffering from liver metastases, Ahar et al were able to show objective response rates (complete and partial response) of 13.9 % and median overall survival of 7.69 months.…”

“…In the largest trial with 42 cutaneous melanoma patients with suffering from liver metastases, Ahar et al were able to show objective response rates (complete and partial response) of 13.9 % and median overall survival of 7.69 months. The smaller studies yielded objective response rates of up to 57 % [554].…”

“…Systematic search of the literature de-novo: [549][550][551][552][553][554][555][556][557][558][559][560][561][562][563][564][565][566] Strength of consensus: 100 %…”

Management of Uveal Melanoma: A Consensus-Based Provincial Clinical Practice Guideline

“…Furthermore, most systemic therapies for metastatic uveal melanoma (largely modelled after therapies for cutaneous melanoma) have failed to demonstrate clinical efficacy in phase ii trials [65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81] . However, immunotherapies, including the anti-ctla4 antibody ipilimumab, have shown some success in retrospective and expanded-access studies [82][83][84][85][86][87] .…”

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

“…During recent years, different treatment approaches have been tested in patients with metastatic UM. Responses have been reported mainly with localized treatment in patients with a limited number of metastases in the liver [2][3][4][5][6]. When diffuse liver involvement and/or extrahepatic disease have developed, systemic therapies are warranted.…”